What is the appropriate dosing and usage of Wixela (fluticasone propionate/formoterol fumarate) for asthma or COPD?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Wixela Dosing and Usage

Wixela (fluticasone propionate/formoterol fumarate) is dosed as 1 inhalation twice daily (approximately 12 hours apart) for both asthma and COPD, with specific strength selection based on disease severity and patient age. 1

Asthma Dosing

Adults and Adolescents (≥12 years)

  • Starting dose: 1 inhalation twice daily of Wixela 100/50,250/50, or 500/50 based on:
    • Previous ICS dose
    • Current symptom control
    • Exacerbation risk 1
  • Maximum dose: Wixela 500/50 twice daily 1
  • Onset: Improvement may occur within 30 minutes, but maximum benefit typically requires 1 week or longer 1
  • Dose adjustment: If inadequate response after 2 weeks, consider stepping up to higher strength 1

Children (4-11 years)

  • Fixed dose: 1 inhalation of Wixela 100/50 twice daily only 1
  • This is the only approved strength for this age group

COPD Dosing

For all COPD patients: 1 inhalation of Wixela 250/50 twice daily 1

  • This is the only approved strength for COPD—higher strengths have not demonstrated efficacy advantage 1
  • Indicated for maintenance treatment of airflow obstruction and reduction of exacerbations in patients with exacerbation history 1

Critical Administration Points

Route: Oral inhalation only 1

Post-inhalation care: Rinse mouth with water without swallowing to reduce oropharyngeal candidiasis risk 1

Rescue therapy: Use short-acting beta2-agonist (SABA) for acute symptoms between doses—never use additional LABA 1

Frequency limitation: More than 1 inhalation twice daily is NOT recommended due to increased adverse effects with higher salmeterol doses 1

Important Contraindications

  • NOT for acute bronchospasm relief in either asthma or COPD 1
  • Never use as monotherapy without the ICS component
  • Patients on Wixela should not use additional LABA for any reason 1

Clinical Context

Wixela Inhub is a generic equivalent of Advair Diskus, containing fluticasone propionate (ICS) and formoterol fumarate (LABA) 2. The formoterol component provides rapid onset of action compared to salmeterol-containing products 3. The device demonstrates comparable in vitro performance and bioequivalence to the reference product across all patient-relevant flow rates 3.

The combination ICS/LABA approach aligns with current guidelines recommending combination therapy for moderate-to-severe persistent asthma 4 and for COPD patients with exacerbation history 5. The fixed-dose combination ensures patients receive anti-inflammatory therapy with each bronchodilator dose, addressing the critical safety concern of LABA monotherapy 6, 7.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.